Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship - PubMed (original) (raw)

doi: 10.1097/01.pas.0000213335.40358.47.

Yonghee Lee, Alexander Miron, Michelle S Hirsch, Colleen Feltmate, Fabiola Medeiros, Michael J Callahan, Elizabeth O Garner, Robert W Gordon, Chandler Birch, Ross S Berkowitz, Michael G Muto, Christopher P Crum

Affiliations

• PMID: 17255760
• DOI: 10.1097/01.pas.0000213335.40358.47

Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship

David W Kindelberger et al. Am J Surg Pathol. 2007 Feb.

Abstract

Proposed origins of pelvic serous carcinoma include the ovary, fallopian tube, and peritoneum. Prophylactic salpingo-oophorectomies in BRCA+ women have recently identified the fimbria as a site of origin for early serous carcinoma (tubal intraepithelial carcinoma or TIC). We explored the relationship of TIC to pelvic serous carcinomas in consecutive cases with complete adnexal exam (SEE-FIM protocol). Cases positive (group A) or negative (group B) for endosalpinx (including fimbria) involvement, were subclassified as tubal, ovarian, or primary peritoneal in origin. Coexisting TIC was recorded in group A when present and p53 mutation status was determined in 5 cases. Of 55 evaluable cases, 41 (75%) were in group A; including tubal (n = 5), peritoneal (n = 6), and ovarian (n = 30) carcinomas. Foci of TIC were identified in 5 of 5, 4 of 6, and 20 of 30, respectively. Ninety-three percent of TICs involved the fimbriae. Five of 5 TICs and concurrent ovarian carcinomas contained identical p53 mutations. Thirteen of 14 cases in group B were classified as primary ovarian carcinomas, 10 with features supporting an origin in the ovary. Overall, 71% and 48% of "ovarian" serous carcinomas had endosalpinx involvement or TIC. TIC coexists with all forms of pelvic serous carcinoma and is a plausible origin for many of these tumors. Further studies are needed to elucidate the etiologic significance of TIC in pelvic serous carcinoma, reevaluate the criteria for tubal, peritoneal, and ovarian serous carcinoma, and define the role of the distal tube in pelvic serous carcinogenesis.

PubMed Disclaimer

Similar articles

• [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
  Liang Y, Chen XD, Lü BJ, Zhou CY, Zhang XF, Shi HY. Liang Y, et al. Zhonghua Fu Chan Ke Za Zhi. 2011 Oct;46(10):724-8. Zhonghua Fu Chan Ke Za Zhi. 2011. PMID: 22321343 Chinese.
• Are all pelvic (nonuterine) serous carcinomas of tubal origin?
  Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM, Vang R. Przybycin CG, et al. Am J Surg Pathol. 2010 Oct;34(10):1407-16. doi: 10.1097/PAS.0b013e3181ef7b16. Am J Surg Pathol. 2010. PMID: 20861711
• p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
  Leonhardt K, Einenkel J, Sohr S, Engeland K, Horn LC. Leonhardt K, et al. Int J Gynecol Pathol. 2011 Sep;30(5):417-24. doi: 10.1097/PGP.0b013e318216d447. Int J Gynecol Pathol. 2011. PMID: 21804388
• The distal fallopian tube: a new model for pelvic serous carcinogenesis.
  Crum CP, Drapkin R, Miron A, Ince TA, Muto M, Kindelberger DW, Lee Y. Crum CP, et al. Curr Opin Obstet Gynecol. 2007 Feb;19(1):3-9. doi: 10.1097/GCO.0b013e328011a21f. Curr Opin Obstet Gynecol. 2007. PMID: 17218844 Review.
• [Fallopian tube: the dark face of pelvic carcinogenesis].
  Watkin E, Devouassoux-Shisheboran M. Watkin E, et al. Ann Pathol. 2011 Oct;31(5):345-52. doi: 10.1016/j.annpat.2011.06.008. Epub 2011 Sep 25. Ann Pathol. 2011. PMID: 21982240 Review. French.

Cited by

• Ovarian cancer: opportunity for targeted therapy.
  Tagawa T, Morgan R, Yen Y, Mortimer J. Tagawa T, et al. J Oncol. 2012;2012:682480. doi: 10.1155/2012/682480. Epub 2011 Dec 22. J Oncol. 2012. PMID: 22235203 Free PMC article.
• Comparison of the Classical Method and SEE-FIM Protocol in Detecting Microscopic Lesions in Fallopian Tubes with Gynecological Lesions.
  Koc N, Ayas S, Arinkan SA. Koc N, et al. J Pathol Transl Med. 2018 Jan;52(1):21-27. doi: 10.4132/jptm.2016.06.17. Epub 2016 Aug 19. J Pathol Transl Med. 2018. PMID: 27539290 Free PMC article.
• Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis.
  Wang Y, Li L, Wang Y, Tang SN, Zheng W. Wang Y, et al. Am J Transl Res. 2016 Jan 15;8(1):230-8. eCollection 2016. Am J Transl Res. 2016. PMID: 27069556 Free PMC article. Retracted.
• The role of the fallopian tube in the origin of ovarian cancer.
  Erickson BK, Conner MG, Landen CN Jr. Erickson BK, et al. Am J Obstet Gynecol. 2013 Nov;209(5):409-14. doi: 10.1016/j.ajog.2013.04.019. Epub 2013 Apr 10. Am J Obstet Gynecol. 2013. PMID: 23583217 Free PMC article. Review.
• Mutant p53 expression in fallopian tube epithelium drives cell migration.
  Quartuccio SM, Karthikeyan S, Eddie SL, Lantvit DD, Ó hAinmhire E, Modi DA, Wei JJ, Burdette JE. Quartuccio SM, et al. Int J Cancer. 2015 Oct 1;137(7):1528-38. doi: 10.1002/ijc.29528. Epub 2015 Apr 11. Int J Cancer. 2015. PMID: 25810107 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wolters Kluwer

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal